Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study

BACKGROUND: Pneumocystis pneumonia (PCP) is increasingly being diagnosed in patients with systemic lupus erythematosus (SLE), and hydroxychloroquine (HCQ) has been found to possess antifungal activities. We hence aimed to investigate the association between HCQ and PCP risk among patients with SLE....

Descripción completa

Detalles Bibliográficos
Autores principales: Yeo, Kai-Jieh, Chen, Hsin-Hua, Chen, Yi-Ming, Lin, Ching-Heng, Chen, Der-Yuan, Lai, Chih-Ming, Chao, Wen-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011312/
https://www.ncbi.nlm.nih.gov/pubmed/32041539
http://dx.doi.org/10.1186/s12879-020-4826-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011312/
https://www.ncbi.nlm.nih.gov/pubmed/32041539
http://dx.doi.org/10.1186/s12879-020-4826-1

Ejemplares similares